<DOC>
	<DOCNO>NCT02359461</DOCNO>
	<brief_summary>The purpose study demonstrate improvement vascular function , particularly dependent vasodilation flow micro-vasculature , STENDO diabetic patient compare control period crossover . Action shear stress cause vasodilation away microcirculation , STENDO beneficial effect vascular function type 2 diabetic . These effect could treble completion session device , chronic potentiate effect different session . The investigator propose study different vascular function evaluation parameter , highlight acute chronic change . The investigator also study physical ability change topic behavioral change ( spontaneous physical activity particular ) impact subject quality life .</brief_summary>
	<brief_title>Evaluation Effect Pulsatile Cuts Stendo3 Vascular Function Patients With Diabetes Type 2</brief_title>
	<detailed_description>Patients screen visit V0 . A collection consent ( informed consent form ) , clinical examination fast blood test carry visit . Laboratory test run-in compose : Cell Blood Count ( CBC ) platelet , renal function test ( serum electrolytes , urea creatinine ) , liver function test , fast blood glucose level Lipid Profile ) . Measurement blood Pressure ( 2 successive measurement interval 5 min ) electrocardiogram realize . The different information collect enrollment allow stratification cardiovascular risk reference integrator score ( ESC-SCORE ( European Society Cardiology Score ) Framingham Heart Study ) . The feasibility measure study criterion ( functional measurement assay ) test fast visit blood test . V0 : Patient Pre-Inclusion : J-5 J-10 - Patient Information - Collection inform consent - Demographic data , weight / height , waist circumference - Interrogation , - Clinical examination , Electrocardiogram - Measuring blood pressure ( 2 successive measurement interval 5 minute ) - ESC-SCORE ( European Society Cardiology Score ) Framingham Heart Study - Criteria inclusion / non inclusion - Functional Measurements ( validate feasibility patient ) - Blood test fasting : Complete Blood Count ( CBC ) platelet , renal function test ( serum electrolytes , urea , creatinine ) , liver function , blood sugar , Lipid Profile . V1 - Day 1 study At V1 , patient clinical examination blood test fast determination endothelial parameter ( Endothelial Micro Particles EMP ) . Subjects randomize two group determine sequence : STENDO control , control STENDO . Furthermore , functional measurement perform baseline , morning fast 12 hour room specially dedicate study vascular reactivity ( calm , stable temperature 23 25 ° C ) . When patient STENDO technical , biological functional assessment renew end first session STENDO ( immediately ) . - Clinical examination - Confirmation inclusion - Allocation randomization - Measuring blood pressure ( 2 successive measurement 5min interval ) - Blood Sample : Endothelial Micro Particles ( EMP ) , Creatinine , Glucose , Glycated Haemoglobin ( HbA1c ) , Lipid profile , Insulin - Analysis 24-hour urine : creatinine microalbuminuria - Functional Measures : Flow-mediated dilatation ( FMD ) , Velocity time integral ( VTI ) , Laser Doppler Flowmetry ( LDF ) , Stiffness central artery SphygmoCor , Stiffness central artery peripheral artery pOpmètre , fast - Measurements physical ability : endurance quadriceps Maximum Voluntary Contraction ( MVC ) , MVC hand , Aerobic capacity ( VO2 max ) , 6 minute Walk Test ( 6MWT ) , International Physical Activity Questionnary - French Version ( IPAQ ) , Physical activity record triaxial accelerometry ( eMouve® ) , - Measurement quality life : Visual Analogic Scale ( VAS ) Short-form 36 Health survey ( SF36 ) . - Stendo Session 1 hour 1 hour rest accord randomization group - Blood Sample : Endothelial Micro Particles ( EMP ) ( STENDO ) - Realization functional measure : FMD , VTI , FLD , SphygmoCor , pOpmètre , fast 1st STENDO session ( STENDO ) For three month , patient benefit one-hour session STENDO three time week . V2 30 day inclusion +/- 1 week V3 60 day inclusion +/- 1 week - intermediate visit V2 V3 intermediate visit avoid lose sight especially monitoring period . An evaluation quality life ( SF-36 VAS ) physical activity ( IPAQ questionnaire control collection eMouve ) make 2 group . V4 90 day inclusion +/- 1 week End 1st period V4 visit take place way V1 visit day last session STENDO ( applicable ) : clinical examination , functional measurement , fast blood test , measure physical function . - Clinical examination - Measuring blood pressure ( 2 successive measurement 5min interval ) - Blood Sample : Endothelial Micro Particles ( EMP ) , Creatinine , Glucose , Glycated Haemoglobin ( HbA1c ) , Lipid profile analysis , Insulin - Functional Measures : Flow-mediated dilatation ( FMD ) , Velocity time integral ( VTI ) , Laser Doppler Flowmetry ( LDF ) , Stiffness central artery SphygmoCor , Stiffness central artery peripheral artery pOpmètre , fast - Measurements physical ability : endurance quadriceps Maximum Voluntary Contraction ( MVC ) , MVC hand , Aerobic capacity ( VO2 max ) , 6 minute Walk Test ( 6MWT ) , International Physical Activity Questionnary - French Version ( IPAQ ) , Physical activity record triaxial accelerometry ( eMouve® ) , - Visual Analogic Scale ( VAS ) Short-form 36 Health survey ( SF36 ) . The time interval V4 V5 minimum 30 day make `` wash-out '' stendo technique . V5 : least 120 day inclusion , least 30 day `` Wash-out '' period Start 2nd period V5 visit first visit second period crossover . This correspond basal measurement second period . The assessment carry V1 measure parameter acute subject start period stendo - Clinical examination - Measuring blood pressure ( 2 successive measurement 5min interval ) - Blood Sample : Endothelial Micro Particles ( EMP ) , Creatinine , Glucose , Glycated Haemoglobin ( HbA1c ) , Lipid profile analysis , Insulin - Functional Measures : Flow-mediated dilatation ( FMD ) , Velocity time integral ( VTI ) , Laser Doppler Flowmetry ( LDF ) , SphygmoCor , pOpmètre , fast - Measurements physical ability : endurance quadriceps Maximum Voluntary Contraction ( MVC ) , MVC hand , Aerobic capacity ( VO2 max ) , 6 Minutes Walk Test ( 6MWT ) , International Physical Activity Questionnary - French Version ( IPAQ ) , Physical activity record triaxial accelerometry ( eMouve® ) , - Visual Analogic Scale ( VAS ) Short-form 36 Health survey ( SF36 ) . If Stendo , three month , patient benefit one-hour session stendo three time week . V6 30 day +/- 1 week 2nd period onset V7 60 day +/- 1 week 2nd period onset - intermediate visit The intermediate visit V6 V7 avoid lose sight especially monitoring period . An evaluation Health-related quality life Visual Analogic Scale ( VAS ) Short-form 36 Health survey ( SF36 ) ) physical activity International Physical Activity Questionnary - French Version ( IPAQ ) Physical activity record triaxial accelerometry ( eMouve® ) make 2 group . V8 90 day +/- 1 week End second period Same measurement V4 visit . Signed investigator end study . The day last session STENDO ( applicable ) : clinical examination , blood functional measurement fast blood test , physical function . - Clinical examination - Measuring blood pressure ( 2 successive measurement 5min interval ) - Blood Sample : Endothelial Micro Particles ( EMP ) , Creatinine , Glucose , Glycated Haemoglobin ( HbA1c ) , Lipid profile analysis , Insulin - Functional Measures : Flow-mediated dilatation ( FMD ) , Velocity time integral ( VTI ) , Laser Doppler Flowmetry ( LDF ) , SphygmoCor , pOpmètre , fast - Measurements physical ability : endurance quadriceps Maximum Voluntary Contraction ( MVC ) , MVC hand , Aerobic capacity ( VO2 max ) , 6 Minutes Walk Test ( 6MWT ) , International Physical Activity Questionnary - French Version ( IPAQ ) , Physical activity record triaxial accelerometry ( eMouve® ) , - Visual Analogic Scale ( VAS ) Short-form 36 Health survey ( SF36 ) . - End study form</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients type 2 diabetes Age ≥ 18 ≤ 75 year Diagnosis diabetes &gt; 2 year Asymptomatic cardiovascular No known heart disease ECG sinus rythm sign suggestive heart disease Absence myocardial ischemia demonstrate stress test , myocardial scintigraphy stress ultrasound Oral treatment antidiabetic / insulin / incretin Affiliated social security scheme Having sign informed consent Type 1 diabetes Previous history cardiomyopathy ischemic heart disease Absence sinus rythm ECG suggest heart disease Electrical malfunction exercise test Hemodynamically significant valvular pathology Severe renal impairment ( GFR &lt; 30 ml / min / 1.73m² ) Uncontrolled hypertension : SBP ≥ 140 mm Hg DBP ≥ 90 mm Hg The introduction modification antihypertensive treatment lead inability include subject two month , time reach new balance . Comorbidity involve lifethreatening BMI &gt; 40 kg /m2 Peripheral vascular disease : Stage 3 IPS ( Index systolic pressure ) uninterpretable doppler diagnose arteritis IPS lower 0.80 Proximal distal arterial bypass ( subpopliteal fossa ) aortic prosthesis Deep vein thrombosis superficial scalable recent low limb pulmonary embolism less one year Unhealed wound low limb abdomen ( ulcer , saphenectomy scar , surgical scarpa abdominal approach ) Disabling painful symptomatology low extremity ( paraesthesia , neuropathy , myalgia ) Treaty selective phosphodiesterase inhibitor ( Sildenafil ... ) Patients cognitive impairment disable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Vascular function</keyword>
	<keyword>Pulsatile cut</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Endothelium</keyword>
	<keyword>Cardiovascular risk</keyword>
	<keyword>Vasomotricity</keyword>
	<keyword>FMD ( Flow Mediated Dilatation )</keyword>
</DOC>